Mark A. Goldberg

Biography

Dr. Goldberg currently is a consultant to several biotechnology companies.  Previously he served as a medical and regulatory strategist for Synageva BioPharma Corp., from October 2014 until June 2015. Prior to that, he had served as Synageva’s Executive Vice President for Medical and Regulatory Strategy and as the Senior Vice President of Medical and Regulatory Affairs. Dr. Goldberg served in a variety of senior management positions at Genzyme Corporation from 1996 to July 2011, including most recently as Senior Vice President and Therapeutic Group Head for Oncology, Genetic and Neurodegenerative Diseases Clinical Development. Prior to working at Genzyme, he was a full-time staff physician at Brigham and Women’s Hospital and Dana Farber Cancer Institute, where he still holds appointments. He has also been an Associate Professor of Medicine at Harvard Medical School since 1996. Dr. Goldberg is a board-certified medical oncologist and hematologist and has more than 50 published papers. Dr. Goldberg currently also serves on the board of directors of ImmunoGen, Inc., Blueprint Medicines, Idera Pharmaceuticals, and aTyr Pharma, all publicly traded companies.  Dr. Goldberg also served on the board of directors of Synageva from October 2008 to December 2011. Since 2010 Dr. Goldberg has served on the board of the New England Division of the American Cancer Society and is currently chair-elect.  He holds an A.B. from Harvard College and an M.D. from Harvard Medical School. 

Research Interest

Medicine